EVER PHARMA

ean european academy of neurology

STROKE

TBI

DEMENTIA

Strongest recommendation for Cerebrolysin® in EAN guideline

Beghi, Ettore, et al. "European Academy of Neurology and European Federation of Neurorehabilitation Societies guideline on pharmacological support in early motor rehabilitation after acute ischaemic stroke." *European Journal of Neurology (2021)*.

- Highest quality evidence
- Best results in all domains
- Proven safety

Cerebrolysin®

Reconnecting Neurons.
Empowering for Life.

1st EAN guideline for neurorehabilitation after stroke

Received: 3 April 2021 | Accepted: 17 May 2021

DOI: 10.1111/ene.14936

european journal of neurology
the official journal of the european academy of neurology

GUIDELINES

European Academy of Neurology and European Federation of Neurorehabilitation Societies guideline on pharmacological support in early motor rehabilitation after acute ischaemic stroke

Ettore Beghi[1] | Heinrich Binder[2] | Codruta Birle[3] | Natan Bornstein[4] | Karin Diserens[5] | Stanislav Groppa[6] | Volker Homberg[7] | Vitalie Lisnic[8] | Maura Pugliatti[9] | Gary Randall[10] | Leopold Saltuari[11] | Stefan Strilciuc[12] | Johannes Vester[13]

The objective of this evidence-based guideline is to support **clinical decision-making** of healthcare professionals involved in the recovery of stroke survivors.

The systematic review was conducted using the recommendations from the **P**referred **R**eporting **I**tems for **S**ystematic Reviews and **M**eta-**A**nalyses **(PRISMA)** and the **Cochrane Handbook** for Systematic Reviews of Interventions. Recommendations were drafted using the **GRADE** framework.

Cerebrolysin® (30 ml/day, intravenous, minimum 10 days) is **recommended for clinical use** for early neurorehabilitation after acute ischaemic stroke.

EAN = largest neurological society worldwide, with 45.000 members

Strongest recommendation for **Cerebrolysin®**

Highest quality evidence

The CARS trials, ECOMPASS and Bornstein meta-analysis were ranked with high-quality evidence in the EAN guideline

Best results in all domains

Cerebrolysin® shows beneficial effects in the domains early motor performance, neurological and global functions

Proven safety

No difference between control group and **Cerebrolysin®** group regarding SAEs (Severe Adverse Events)

Recommendation in EAN guideline FOR USE

Cerebrolysin® included in PAN-EUROPEAN GUIDELINE!

> This guideline found **sufficient evidence** to **recommend use of Cerebrolysin®** in moderate–severe cases, as an add-on therapy **to standard rehabilitation, initiated in the first 7 days after stroke...**

Recommended treatment of **Cerebrolysin®**



Official dosage recommendation

Disorder	Daily dosage	Initiation of treatment	Duration of treatment
Stroke	20 - 50ml	as soon as possible	10 - 21 days

Title: European Academy of Neurology and European Federation of Neurorehabilitation Societies guideline on pharmacological support in early motor rehabilitation after acute ischaemic stroke

https://doi.org/10.1111/ene.14936

Authors: E. Beghi et al.

ABREVIATED PRESCRIBING INFORMATION. Name of the medicinal product: Cerebrolysin - Solution for injection. Qualitative and quantitative composition: One ml contains 215.2 mg of porcine brain-derived peptide preparation (Cerebrolysin concentrate) in aqueous solution. List of excipients: Sodium hydroxide and water for injection. Therapeutic indications: Organic, metabolic and neurodegenerative disorders of the brain, especially senile dementia of Alzheimer's type - Post-apoplectic complications - Craniocerebral trauma; post-operative trauma, cerebral contusion or concussion. Contraindications: Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Marketing Authorisation Holder: EVER Neuro Pharma GmbH, A-4866 Unterach. Only available on prescription and in pharmacies. More information about pharmaceutical form, posology and method of administration, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdose, pharmacodynamics properties, pharmacokinetic properties, preclinical safety data, incompatibilities, shelf life, special precautions for storage, nature and contents of the container and special precautions for disposal is available in the summary of product characteristics.

Copyright © 2016 by EVER Neuro Pharma GmbH, Oberburgau 3, 4866 Unterach, Austria. All rights reserved. No part of this brochure may be reproduced in any form or by any electronic or mechanical means, including information storage and retrieval systems, without permission in writing from the publisher. Cerebrolysin is a registered trademark of EVER Neuro Pharma GmbH, 4866 Unterach, Austria000

Number: CERE/INT/07/2021-14